PPIDT00105
Drug Information
| Name | Exenatide |
|---|---|
| Sequence | HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS |
| DrugBank_ID | DB01276 |
| Type | biotech |
| Indication | Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old,[L45118] while the immediate-acting formulation is approved only for adult patients.[L42690] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Solution | Parenteral |
250.000 mcg
|
| Injection | Subcutaneous |
2 mg
|
| Injection, powder, for suspension, extended release; kit | Subcutaneous |
2 mg / dose
|
| Injection, powder, for suspension; kit | Subcutaneous |
2 mg/0.65mL
|
| Injection, suspension | Parenteral; Subcutaneous |
2 MG
|
| Injection, suspension | Subcutaneous |
2 MG
|
| Injection, suspension, extended release | Subcutaneous |
2 mg/0.65mL
|
| Kit | Subcutaneous |
2 mg/0.65mL
|
| Suspension | Subcutaneous |
|
| Powder | Subcutaneous |
2 mg
|
| Injection, suspension, extended release | Subcutaneous |
2 mg/0.85mL
|
| Suspension, extended release | Subcutaneous |
2 mg / dose
|
| Injection, powder, for suspension, extended release | Subcutaneous |
2 mg
|
| Suspension | Subcutaneous |
200000 mg
|
| Injection, powder, for suspension | Subcutaneous |
200000 mg
|
| Injection | Subcutaneous |
|
| Injection | Subcutaneous |
250 ug/1mL
|
| Injection, solution | Parenteral; Subcutaneous |
10 MICROGRAMMI
|
| Injection, solution | Parenteral; Subcutaneous |
5 MICROGRAMMI
|
| Injection, solution | Subcutaneous |
10 micrograms
|
| Injection, solution | Subcutaneous |
5 micrograms
|
| Solution | Subcutaneous |
10 mcg / act
|
| Solution | Subcutaneous |
5 mcg / act
|
| Solution | Subcutaneous |
10 ug/40uL
|
| Solution | Subcutaneous |
5 ug/20uL
|
| Injection, powder, for solution | — |
|
| Solution | Subcutaneous |
25000000 mcg
|
| Powder | — |
1 g/1g
|